APPLICATION OF TRADITIONAL CHINESE MEDICINE COMPOSITION IN PREPARATION OF DRUGS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION

Abstract

An application of a traditional Chinese medicine composition in preparing a medicine for treating or preventing coronavirus infection. The traditional Chinese medicine composition is characterized by being prepared from the following raw materials in parts by weight: 5-15 parts of Cornu saigae tataricae or 50-150 parts of goral horns, 10-60 parts of Bulbus Fritillariae Ussuriensis, 15-60 parts of Radix et Rhizoma Rhei, 7-30 parts of Radix scutellariae, 7-30 parts of Lapis Chloriti, 10-50 parts of gypsum fibrosum, 5-20 parts of calculus bovis artifactus, and 15-60 parts of radix glycyrrhizae. The traditional Chinese medicine composition can inhibit 2019-nCoV replication in cells, so that cells infected by 2019-nCoV viruses have no lesion. Therefore, the traditional Chinese medicine composition can treat or prevent coronavirus related diseases.

Claims

1-9. (canceled)

10. An application of a traditional Chinese medicine composition in preparing a medicine for treating or preventing coronavirus infection, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5-15 parts of cornu saigae tataricae or 50-150 parts of goral horns, 10-60 parts of Bulbus Fritillariae Ussuriensis, 15-60 parts of Radix et Rhizoma Rhei, 7-30 parts of radix scutellariae, 7-30 parts of Lapis Chloriti, 10-50 parts of gypsum fibrosum, 5-20 parts of calculus bovis artifactus, and 15-60 parts of radix glycyrrhizae.

11. The application according to claim 10, wherein the coronavirus infection comprises infection of COVID-19.

12. The application according to claim 10, wherein the traditional Chinese medicine composition comprises: 8-12 parts of cornu saigae tataricae or 80-120 parts of goral horns, 15-55 parts of Bulbus Fritillariae Ussuriensis, 20-35 parts of Radix et Rhizoma Rhei, 10-18 parts of radix scutellariae, 10-18 parts of Lapis Chloriti, 15-25 parts of gypsum fibrosum, 8-12 parts of calculus bovis artifactus, and 20-35 parts of radix glycyrrhizae.

13. The application according to claim 10, wherein the traditional Chinese medicine composition comprises: 9.45 parts of cornu saigae tataricae, 17.25 parts of Bulbus Fritillariae Ussuriensis, 31.5 parts of Radix et Rhizoma Rhei, 15.75 parts of radix scutellariae, 15.75 parts of Lapis Chloriti, 23.62 parts of gypsum fibrosum, 9.45 parts of calculus bovis artifactus, and 31.5 parts of radix glycyrrhizae.

14. The application according to claim 10, wherein the traditional Chinese medicine composition comprises: 94.5 parts of goral horns, 47.25 parts of Bulbus Fritillariae Ussuriensis, 31.5 parts of Radix et Rhizoma Rhei, 15.75 parts of radix scutellariae, 15.75 parts of Lapis Chloriti, 23.62 parts of gypsum fibrosum, 9.45 parts of calculus bovis artifactus, and 31.5 parts of radix glycyrrhizae.

15. The application according to claim 10, wherein the medicine for treating or preventing coronavirus infection comprises an oral dosage form, an injection administration form, or an external administration preparation.

16. The application according to claim 15, wherein the medicine for treating or preventing coronavirus infection comprises a decoction, a tablet, a capsule, a granule, a pill, an injection, a decocted extract, a suspending agent, a dispersing agent, a syrup, a suppository, a gel, an aerosol, a patch, or an oral liquid.

17. The application according to claim 10, wherein a method for preparing the traditional Chinese medicine composition comprises the following steps: taking and cutting the cornu saigae tataricae or goral horns into threads; hydrolyzing the threads with an alkaline-containing aqueous solution; filtering, and taking and concentrating filtrate; taking and smashing the Lapis Chloriti and gypsum fibrosum; heating and decocting the smashed Lapis Chloriti and gypsum fibrosum in water; filtering, and taking and concentrating filtrate; taking and extracting the calculus bovis artifactus with 70% alcohol; filtering, and concentrating filtrate; decocting a rest of medicines in water; concentrating and centrifuging filtrate; precipitating liquid supernatant with alcohol; standing, taking the liquid supernatant, filtering, and concentrating filtrate; and mixing the concentrated filtrate to obtain the traditional Chinese medicine composition.

18. The application according to claim 17, wherein the cornu saigae tataricae or goral horns are cut into threads, the alkaline-containing aqueous solution is used to perform hydrolysis reflux twice, and filtrate obtained twice is concentrated; the Lapis Chloriti and gypsum fibrosum are smashed into crude powder, the crude powder is heated and decocted twice in water, filtering is performed, filtrate obtained twice is combined, and the combined filtrate is concentrated to have a relative density of 1.01 to 1.04 at 75° C. to 85° C.; reflux and extraction is performed on calculus bovis artifactus with 70% alcohol twice, filtering is performed, filtrate obtained twice is combined, alcohol is recycled under reduced pressure, and the combined filtrate is concentrated to have a relative density of 1.02 to 1.05 at 75° C. to 85° C.; the rest of medicines are decocted in water twice, and filtered, and filtrate obtained twice is combined, the combined filtrate is concentrated to have a relative density of 1.10 at 85° C., and is centrifuged, liquid supernatant is precipitated by adding alcohol, and is taken and filtrated after standing is performed, alcohol is recycled under reduced pressure, and then filtrate is concentrated to have a relative density of 1.08 at 85° C.; and the concentrated filtrate is mixed to obtain the traditional Chinese medicine composition.

Description

DETAILED DESCRIPTION OF EMBODIMENTS

[0019] The present application discloses a use of a traditional Chinese medicine composition, a person skilled in the art appropriately improve the process parameters with reference to the content of this application. It should be noted that all such alternations and modifications are obvious to a person skilled in the art and are considered to be included in the present application. The method of the present application has been described by way of a preferred embodiment, and it is obvious that the method described herein can be modified or appropriately changed and combined to realize and apply the technology of the present application without departing from the scope, spirit and scope of the present application.

[0020] Unless otherwise specified, drugs, biomaterials or apparatuses adopted in the present application are common market products, and can be purchased on the market.

[0021] The present application is further illustrated in detail in combination with embodiments hereinafter.

Embodiment 1 Preparation of Traditional Chinese Medicine Oral Liquid

[0022] 94.5 g of goral horns was cut into threads, an alkaline-containing aqueous solution was used to perform hydrolysis reflux twice, filtrate obtained twice filtrate was combined and concentrated; 15.75 g of Lapis Chloriti and 23.62 g of gypsum were smashed into crude powder, the crude powder was heated and decocted twice in water, filtering was performed, filtrate obtained twice was obtained, and the combined filtrate was concentrated to have a relative density of 1.01 to 1.04 at 75 DEG C (° C.) to 85 DEG C (° C.); reflux and extraction were performed on 9.45 g of calculus bovis artifactus with 70% alcohol twice, filtering was performed, filtrate obtained twice was combined, alcohol was recycled under reduced pressure, and the filtrate was concentrated to have a relative density of 1.02 to 1.05 at 75 DEG C (° C.) to 85 DEG C (° C.); the rest of four medicines: 47.25 g of Bulbus Fritillariae Ussuriensis, 31.5 g of Radix et Rhizoma Rhei, 15.75 parts of radix scutellariae and 31.5 g of radix glycyrrhizae were decocted in water twice, filtering was performed, filtrate obtained twice was combined, the filtrate was concentrated to have a relative density of 1.10 at 85 DEG C (° C.), and was centrifuged, liquid supernatant was precipitated by adding alcohol, standing was performed, the liquid supernatant was taken and filtered, alcohol was recycled under reduced pressure, and the filtrate was concentrated to have a relative density of 1.08 at 85 DEG C (° C.); and the concentrated filtrate was mixed to obtain the traditional Chinese medicine composition.

[0023] The concentrated liquor was uniformly mixed with 0.2% steviosin, water was added to 1000 ml, uniformly mixing was performed, boiling was performed for 40 minutes, refrigerating was performed for not less than 48 h, filtering was performed, water was added into the filtrate until 1000 ml, a pH value of the filtrate was adjusted to be 8.0-9.0, filling was performed, and sterilizing was performed to obtain the traditional Chinese medicine composition.

Efficacy Test Example

[0024] 1. Experimental Materials

[0025] Tested medicines: medicines prepared in Embodiment 1 of the present application.

[0026] VeroE6 cell: Stored in Pathogen Center, Institute of Medical Laboratory Animal, Chinese Academy of Medical Sciences.

[0027] 2019-nCoV virus: with titer of 10.sup.5TCID.sub.50/ml, stored at −80 DEG C (° C.) in Pathogen Center, Institute of Medical Laboratory Animal, Chinese Academy of Medical Sciences. Viral titer used is 100TCID.sub.50.

[0028] 2. Experimental Method

[0029] In a sterile 96-well culture plate, 200 μl of a Vero E6 cell with a concentration of 5×10.sup.4 cell/ml was added into each well, and was cultured with 5% CO.sub.2 for 24 hours at 37 DEG C (° C.); a tested medicine was diluted to have three concentrations: (1:10000, 1:20000 and 1:50000), five wells for each concentration, 100 μl in each well; an equal volume of 100 TCID50 virus was added into each well, and was incubated for 1 h; 1 h later, cell culture fluid in the 96-well culture plate was discarded, and the medicine mixed liquor was added; cell control, blank control (solvent control) and virus control (negative control) were set at the same time; the cell was incubated in an incubator with 5% CO.sub.2 at 37 DEG C (° C.) for 4-5 days. Cytopathic effect (CPE) was observed under an optical microscope, complete cell cytopathy was recorded as “++++”, 75% cell cytopathy was recorded as “+++”, 50% cell cytopathy was recorded as “++”, 25% cell cytopathy was recorded as “+”, and no cell cytopathy was recorded as “−”.

[0030] 3. Experimental Conditions: The Experimental Operations were all Completed in a BSL-3 Laboratory.

[0031] 4. Result judgment: when the cell had no CPE, the concentration could effectively inhibit the virus; and when the cell had CPE, the concentration was ineffective.

[0032] 5. Experimental Results:

[0033] The medicine group was set with three concentrations at which 2019-nCoV replication in the cell could be effectively inhibited. The results were shown in table 1.

TABLE-US-00001 TABLE 1 Anti-2019-nCoV effect of medicines Names of tested medicines Concentration Results Medicines of 1:10000 − the present 1:20000 − application 1:50000 − Negative control/ ++++ cytotoxicity Notes: “−”indicated no cytopathy, and “++++” indicated complete cell cytopathy.

[0034] 6. Conclusion:

[0035] Based on a cell-level screening result, a sample prepared in Embodiment 1 of the present application could inhibit the 2019-nCoV replication in the cell at 1:10000, 1:20000 and 1:50000 dilution concentrations. This indicated that the medicine in the present application had good in-vitro anti-2019-nCov activity.

[0036] It should be noted that a person skilled in the art can properly improve process parameters with reference to the content of this application. All such alternations and modifications are obvious to the person skilled in the art and are considered to be included in the present application.